Home LiteratureArticle Details
PMID: 24829747 Published · epublish English Journal Article Review

Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.

Journal for immunotherapy of cancer ·Vol. 1 ·2013-00-00 ·Pages 10

Wesolowski R, Markowitz J, Carson WE

Abstract

Myeloid Derived Suppressor Cells (MDSC) are a heterogeneous population of immature myeloid cells that are increased in states of cancer, inflammation and infection. In malignant states, MDSC are induced by tumor secreted growth factors. MDSC play an important part in suppression of host immune responses through several mechanisms such as production of arginase 1, release of reactive oxygen species and nitric oxide and secretion of immune-suppressive cytokines. This leads to a permissive immune environment necessary for the growth of malignant cells. MDSC may also contribute to angiogenesis and tumor invasion. This review focuses on currently available strategies to inhibit MDSC in the treatment of cancer.

Keywords
Cancer vaccines Immunotherapy Myeloid derived suppressor cells Tumor immunology
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Wesolowski Robert
Division of Medical Oncology, B401 Starling Loving Hall, W10th Avenue, Columbus, OH 43210, USA.
Markowitz Joseph
Division of Medical Oncology, 406C Starling Loving Hall 320 W 10th Ave, Columbus, OH 43210, USA.
Carson William E
The Ohio State University Comprehensie Cancer Center, N911 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210, USA.
References (81)
81 references, click to expand
  1. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
    J Exp Med. 2006 Nov 27;203(12):2691-702 PMID: 17101732
  2. Myeloid derived suppressor cells in human diseases.
    Int Immunopharmacol. 2011 Jul;11(7):802-7 PMID: 21237299
  3. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
    Int Immunopharmacol. 2007 Feb;7(2):140-51 PMID: 17178380
  4. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  5. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.
    J Immunol. 2010 Mar 15;184(6):3106-16 PMID: 20142361
  6. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
    Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90 PMID: 15753302
  7. Regulation of T cell receptor CD3zeta chain expression by L-arginine.
    J Biol Chem. 2002 Jun 14;277(24):21123-9 PMID: 11950832
  8. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
    Carcinogenesis. 2008 Oct;29(10):2035-43 PMID: 18689872
  9. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
    Eur J Immunol. 2012 Aug;42(8):2060-72 PMID: 22653638
  10. Nuclear retinoid receptors and the transcription of retinoid-target genes.
    Gene. 2004 Mar 17;328:1-16 PMID: 15019979
  11. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.
    Blood. 2008 Jun 15;111(12):5457-66 PMID: 18375791
  12. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Science. 2011 Mar 25;331(6024):1565-70 PMID: 21436444
  13. A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.
    J Immunol. 2011 Nov 15;187(10):4935-46 PMID: 22013118
  14. IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs.
    J Immunol. 2000 Nov 1;165(9):5245-54 PMID: 11046058
  15. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
    Clin Cancer Res. 2007 Aug 15;13(16):4840-8 PMID: 17699863
  16. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.
    Clin Cancer Res. 2008 Dec 15;14(24):8270-8 PMID: 19088044
  17. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis.
    Immunology. 2011 Jun;133(2):221-38 PMID: 21453419
  18. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
    Cancer Res. 2007 May 1;67(9):4507-13 PMID: 17483367
  19. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
    Cancer Immunol Immunother. 2012 Feb;61(2):255-263 PMID: 22120756
  20. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
    J Immunol. 2008 Oct 1;181(7):4666-75 PMID: 18802069
  21. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
    Clin Cancer Res. 2008 May 15;14(10):3185-92 PMID: 18483387
  22. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.
    Cancer Immunol Immunother. 2011 Sep;60(9):1269-79 PMID: 21604071
  23. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.
    Cancer Res. 2012 Jul 1;72(13):3196-206 PMID: 22552283
  24. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
    Blood. 2008 Apr 15;111(8):4233-44 PMID: 18272812
  25. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
    Cancer Immunol Immunother. 2011 Oct;60(10):1419-30 PMID: 21644036
  26. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand.
    Cell. 2002 May 31;109(5):625-37 PMID: 12062105
  27. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
    J Exp Med. 2008 Sep 29;205(10):2235-49 PMID: 18809714
  28. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
    Cancer Immunol Immunother. 2004 Oct;53(10):879-92 PMID: 15338206
  29. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC).
    Cancer Immunol Immunother. 2012 Aug;61(8):1319-25 PMID: 22546994
  30. The efficacy of an IL-1alpha vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction.
    J Immunother. 2009 Jul-Aug;32(6):552-64 PMID: 19483654
  31. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.
    Immunol Res. 2011 Aug;50(2-3):276-85 PMID: 21717082
  32. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Clin Cancer Res. 2005 Sep 15;11(18):6713-21 PMID: 16166452
  33. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
    J Exp Med. 2011 Sep 26;208(10):1949-62 PMID: 21930770
  34. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Int Immunopharmacol. 2009 Jul;9(7-8):900-9 PMID: 19336265
  35. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice.
    J Nutr. 2004 Oct;134(10):2653-9 PMID: 15465762
  36. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    J Immunol. 2005 Aug 1;175(3):1619-27 PMID: 16034101
  37. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
    Mol Cancer. 2010 Aug 16;9:217 PMID: 20712901
  38. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.
    Antioxid Redox Signal. 2007 Nov;9(11):1963-70 PMID: 17822364
  39. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.
    Clin Cancer Res. 2012 Mar 15;18(6):1672-83 PMID: 22291136
  40. Antitumor properties of histamine in vivo.
    Nat Med. 2011 May;17(5):537; author reply 537-8 PMID: 21546964
  41. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Clin Cancer Res. 2009 Mar 15;15(6):2148-57 PMID: 19276286
  42. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells.
    Mol Immunol. 2013 May;54(1):74-83 PMID: 23220070
  43. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.
    Cancer Immunol Immunother. 2004 May;53(5):422-30 PMID: 14648070
  44. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
    Cancer Res. 2011 Aug 1;71(15):5101-10 PMID: 21680779
  45. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
    Cancer Immunol Immunother. 2012 Sep;61(9):1373-85 PMID: 22215137
  46. Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer.
    Clin Cancer Res. 2011 Mar 1;17(5):1012-23 PMID: 21248302
  47. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
    BMC Cancer. 2010 Aug 30;10:464 PMID: 20804550
  48. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
    Clin Cancer Res. 2011 Apr 1;17(7):1765-75 PMID: 21233400
  49. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells.
    Nat Med. 2011 Jan;17(1):87-95 PMID: 21170045
  50. Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer.
    Cancer Biother Radiopharm. 2012 Oct;27(8):495-503 PMID: 22746287
  51. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
    Cancer Res. 2006 Sep 15;66(18):9299-307 PMID: 16982775
  52. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
    Cancer Res. 2010 Apr 15;70(8):3052-61 PMID: 20388795
  53. Histamine enhances granulocyte-macrophage colony-stimulating factor and interleukin-6 production by human peripheral blood mononuclear cells.
    J Leukoc Biol. 1995 Oct;58(4):445-50 PMID: 7561521
  54. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.
    J Immunol. 2010 Mar 1;184(5):2281-8 PMID: 20118280
  55. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
    Cancer Res. 2009 Feb 15;69(4):1553-60 PMID: 19201693
  56. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Cancer Immunol Immunother. 2011 Jan;60(1):99-109 PMID: 20960189
  57. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
    Clin Cancer Res. 2010 Mar 15;16(6):1812-23 PMID: 20215551
  58. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.
    J Clin Invest. 2009 May;119(5):1093-108 PMID: 19363294
  59. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
    J Exp Med. 2005 Oct 3;202(7):931-9 PMID: 16186186
  60. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  61. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy.
    J Immunother. 2000 Jan;23(1):115-24 PMID: 10687144
  62. Therapeutic targeting of myeloid-derived suppressor cells.
    Curr Opin Pharmacol. 2009 Aug;9(4):470-81 PMID: 19616475
  63. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
    J Immunol. 2007 Jul 15;179(2):977-83 PMID: 17617589
  64. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Cancer Res. 2007 Aug 1;67(15):7477-86 PMID: 17671218
  65. Arginase activity is inhibited by L-NAME, both in vitro and in vivo.
    J Enzyme Inhib Med Chem. 2002 Aug;17(4):267-70 PMID: 12530480
  66. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
    J Clin Invest. 2011 Dec;121(12):4746-57 PMID: 22056381
  67. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.
    Blood. 2010 Feb 18;115(7):1461-71 PMID: 20008303
  68. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.
    Cancer Res. 2008 Jul 1;68(13):5439-49 PMID: 18593947
  69. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
    Mol Cancer. 2010 Jun 25;9:165 PMID: 20576164
  70. Modulators of arginine metabolism support cancer immunosurveillance.
    BMC Immunol. 2009 Jan 09;10:1 PMID: 19134173
  71. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
    J Clin Oncol. 2012 Mar 20;30(9):1005-14 PMID: 22355058
  72. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.
    Cancer Res. 2003 Aug 1;63(15):4441-9 PMID: 12907617
  73. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
    Int J Cancer. 2011 Nov 1;129(9):2158-70 PMID: 21170961
  74. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
    Cancer Res. 2013 May 1;73(9):2782-94 PMID: 23418320
  75. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
    J Immunother. 2012 Feb-Mar;35(2):107-15 PMID: 22306898
  76. Bisphosphonates: mechanisms of action.
    J Clin Invest. 1996 Jun 15;97(12):2692-6 PMID: 8675678
  77. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine.
    J Biol Chem. 1991 Apr 5;266(10):6259-63 PMID: 1706713
  78. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.
    Cancer Res. 2008 Apr 15;68(8):2920-6 PMID: 18413761
  79. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα.
    Eur J Immunol. 2012 Aug;42(8):2052-9 PMID: 22673957
  80. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.
    Cancer Res. 2007 Dec 1;67(23):11438-46 PMID: 18056472
  81. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
Article Info
Journal
Journal for immunotherapy of cancer
Abbr.
J Immunother Cancer
ISSN
2051-1426
DOI
10.1186/2051-1426-1-10
Published
2013-00-00
Epub
2013-00-15
Pages
10
Language
English
Region
England
NLM ID
101620585
PMCID
PMC4019895
Grants
NCI NIH HHS · P01 CA095426 · United States
External Links
PubMed source DOI: 10.1186/2051-1426-1-10 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2